However, T-DXd showed moderate antiproliferative activity only in HCT116 cells with IC50 values of 53.16 μg/mL but not COLO205, P53R and RKO cells, and trastuzumab did not show apparent cytotoxicity in these HER2-positive CRC cell lines (Fig. 1F). Here, ERBB2 is linked to colorectal carcinoma.